Josué Lacerda de Souza
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Josué Lacerda de Souza has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
- José Pereira de Moura Neto
Programa de Pós-Graduação em Imunologia Básica e Aplicada, Universidade Federal do Amazonas , Manaus, Amazonas
2 shared publications - Rajendranath Ramasawmy
Programa de Pós-Graduação em Biodiversidade e Biotecnologia da Amazonia Legal (Rede Bionorte), Universidade do Estado do Amazonas , Manaus
2 shared publications - Ana Vitoria Sena Gouveia
Faculdade de Medicina, Universidade Nilton Lins , Manaus, Amazonas
1 shared publication - Antonio Luiz Boechat
Programa de Pós-Graduação em Imunologia Básica e Aplicada, Universidade Federal do Amazonas , Manaus, Amazonas
1 shared publication Aya Sadahiro
Programa de Pós-Graduação em Imunologia Básica e Aplicada, Universidade Federal do Amazonas , Manaus, Amazonas
1 shared publication- Aya Sadahiro
Programa de Pós-Graduação em Imunologia Básica e Aplicada, Universidade Federal do Amazonas, Manaus 69060001, Amazonas, Brazil
1 shared publication
Latest Publications
- 30 March 2026
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 234 (3) , 439-448
Contrasting Genetic Effects Within STAT4 Define Susceptibility and Protection in Leishmania guyanensis Cutaneous Leishmaniasis
Background: Leishmania guyanensis-associated cutaneous leishmaniasis (CL) is endemic in the Brazilian Amazonas. Despite similar exposure to the pathogen in endemic areas, only a subset of individuals develops disease, suggesting host-genetic control. STAT4 triggers interleukin 12 (IL-12)–dependent Th1 differentiation and interferon-γ (IFN-γ) production, essential for macrophage-mediated parasite clearance. Methods: We performed a case-control study of 802 patients with L. guyanensis CL and 842 endemic controls (ECs). Eleven STAT4 variants (10 SNVs and 1 insertion/deletion) were genotyped. Associations were assessed using logistic regression adjusted for age and sex across multiple genetic models, with haplotype analysis adjusted for age and sex via omnibus and likelihood ratio tests. Results: Two SNVs exerted contrasting associations: the rs1031509 T allele increased susceptibility (adjusted odds ratio [ORadj] = 1.5; 95% CI, 1.3–1.7; adjusted P value, Bonferroni correction [Padj-B] = 1.3 × 10−5), while the rs6434435 A allele conferred protection (ORadj = 0.56; 95% CI, .43−.68; Padj-B = 2.6 × 10−8). Omnibus haplotype analysis revealed significant global differences in haplotype distribution between L. guyanensis CL and ECs (omnibus unadjusted χ2 = 55.65, df = 13, P = 3.11 × 10−7; likelihood ratio test χ2 = 67.81, df = 13, P = 2.02 × 10−9), with a specific high-risk combination (AIGAAAGCTGC) associated with a 9-fold increase in susceptibility (adjusted OR = 9.12; 95% CI, 4.22–19.70; P = 1.9 × 10−8; FDR q = 2.4 × 10−7). Genotype-cytokines analyses revealed that carriers of the protected rs6434435 A allele had significantly higher TNF-α plasma levels under dominant model (+40.2%, FDR adjusted P = .026) and additive model, with a nominal trend toward elevated IFN-γ. Conclusions: Haplotypic variation at this locus significantly shapes host inflammatory responses, highlighting STAT4 as a key immunogenetic determinant of resistance to Leishmania infection.
- 30 March 2026
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 234 (3) , 439-448
Contrasting Genetic Effects Within STAT4 Define Susceptibility and Protection in Leishmania guyanensis Cutaneous Leishmaniasis
Background: Leishmania guyanensis-associated cutaneous leishmaniasis (CL) is endemic in the Brazilian Amazonas. Despite similar exposure to the pathogen in endemic areas, only a subset of individuals develops disease, suggesting host-genetic control. STAT4 triggers interleukin 12 (IL-12)–dependent Th1 differentiation and interferon-γ (IFN-γ) production, essential for macrophage-mediated parasite clearance. Methods: We performed a case-control study of 802 patients with L. guyanensis CL and 842 endemic controls (ECs). Eleven STAT4 variants (10 SNVs and 1 insertion/deletion) were genotyped. Associations were assessed using logistic regression adjusted for age and sex across multiple genetic models, with haplotype analysis adjusted for age and sex via omnibus and likelihood ratio tests. Results: Two SNVs exerted contrasting associations: the rs1031509 T allele increased susceptibility (adjusted odds ratio [ORadj] = 1.5; 95% CI, 1.3–1.7; adjusted P value, Bonferroni correction [Padj-B] = 1.3 × 10−5), while the rs6434435 A allele conferred protection (ORadj = 0.56; 95% CI, .43−.68; Padj-B = 2.6 × 10−8). Omnibus haplotype analysis revealed significant global differences in haplotype distribution between L. guyanensis CL and ECs (omnibus unadjusted χ2 = 55.65, df = 13, P = 3.11 × 10−7; likelihood ratio test χ2 = 67.81, df = 13, P = 2.02 × 10−9), with a specific high-risk combination (AIGAAAGCTGC) associated with a 9-fold increase in susceptibility (adjusted OR = 9.12; 95% CI, 4.22–19.70; P = 1.9 × 10−8; FDR q = 2.4 × 10−7). Genotype-cytokines analyses revealed that carriers of the protected rs6434435 A allele had significantly higher TNF-α plasma levels under dominant model (+40.2%, FDR adjusted P = .026) and additive model, with a nominal trend toward elevated IFN-γ. Conclusions: Haplotypic variation at this locus significantly shapes host inflammatory responses, highlighting STAT4 as a key immunogenetic determinant of resistance to Leishmania infection.
- Open Access
- 19 November 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (22) , 12438
Caspase-1 Variants and Plasma IL-1β in Patients with Leishmania guyanensis Cutaneous Leishmaniasis in the Amazonas
Leishmaniasis, a disease caused by protozoan Leishmania spp., exhibits a broad range of clinical manifestations. Host resistance or susceptibility to infections is often influenced by the genetic make-up associated with natural immunity. Caspase-1, a key component of the NLRP3 inflammasome, is critical for processing pro-IL-1β into its active form, IL-1β, while CARD8 functions as an NLRP3 inflammasome inhibitor. We conducted a case–control study comparing L. guyanensis-cutaneous leishmaniasis (Lg-CL) patients with healthy individuals (HCs) by analyzing the CASP1 genetic variants rs530537A>G, rs531542C>T, rs531604A>T and rs560880G>T. Additionally, a combined analysis of CARD8rs2043211A>T with CASP1rs530537 was performed. The genotype distribution for the four variants showed no significant differences between Lg-CL patients and HCs. However, the haplotype analysis of the four CASP1 variants identified the GTTT haplotype as associated with a 19% decreased likelihood of Lg-CL development, suggesting a protective effect against disease progression. The combined analysis of CARD8 with CASP1 variants indicated that individuals homozygous for both variants (GG/TT) exhibited a 38% reduced risk of developing Lg-CL (OR = 0.62 [95%CI:0.46–0.83]) in comparison to individuals with other genotype combinations. No correlation was found between the CASP1 variant genotypes and plasma IL-1β levels. CASP1 may act as a genetic modifier in Lg-CL.
- 19 November 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (22) , 12438
Open AccessCaspase-1 Variants and Plasma IL-1β in Patients with Leishmania guyanensis Cutaneous Leishmaniasis in the Amazonas
Leishmaniasis, a disease caused by protozoan Leishmania spp., exhibits a broad range of clinical manifestations. Host resistance or susceptibility to infections is often influenced by the genetic make-up associated with natural immunity. Caspase-1, a key component of the NLRP3 inflammasome, is critical for processing pro-IL-1β into its active form, IL-1β, while CARD8 functions as an NLRP3 inflammasome inhibitor. We conducted a case–control study comparing L. guyanensis-cutaneous leishmaniasis (Lg-CL) patients with healthy individuals (HCs) by analyzing the CASP1 genetic variants rs530537A>G, rs531542C>T, rs531604A>T and rs560880G>T. Additionally, a combined analysis of CARD8rs2043211A>T with CASP1rs530537 was performed. The genotype distribution for the four variants showed no significant differences between Lg-CL patients and HCs. However, the haplotype analysis of the four CASP1 variants identified the GTTT haplotype as associated with a 19% decreased likelihood of Lg-CL development, suggesting a protective effect against disease progression. The combined analysis of CARD8 with CASP1 variants indicated that individuals homozygous for both variants (GG/TT) exhibited a 38% reduced risk of developing Lg-CL (OR = 0.62 [95%CI:0.46–0.83]) in comparison to individuals with other genotype combinations. No correlation was found between the CASP1 variant genotypes and plasma IL-1β levels. CASP1 may act as a genetic modifier in Lg-CL.